Patricia Ines Mendoza Zulueta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Patricia Ines Mendoza Zulueta has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Anvit Rai
Albert Einstein College of Medicine, New York, NY 10461, USA
1 shared publication - Caterina P. Minniti
Division of Hematology, Department of Medicine Albert Einstein College of Medicine/Montefiore Medical Center Bronx New York USA
1 shared publication Hannah Kim
Feinberg School of Medicine, Northwestern University, Chicago, IL; and
1 shared publication- Jee-Young Moon
Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
1 shared publication - Shailee Shah
Feinberg School of Medicine, Northwestern University, Chicago, IL; and
1 shared publication - Tiana J. Geringer
Department of Ophthalmology & Visual Sciences, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY 10461, USA
1 shared publication
Latest Publications
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Teaching NeuroImage: Opioid-Associated Amnestic Syndrome
- 24 November 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (10)
Teaching NeuroImage: Opioid-Associated Amnestic Syndrome
- Open Access
- 16 February 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (4) , 3451
Routine Ophthalmological Examination Rates in Adults with Sickle Cell Disease Are Low and Must Be Improved
The American Academy of Ophthalmology and the National Heart, Lung and Blood Institute recommend patients with sickle cell disease (SCD) undergo dilated funduscopic exams (DFE) every 1–2 years to screen for sickle retinopathy. There is a paucity of data on the adherence rate to these guidelines; a retrospective study was performed to evaluate our institution’s adherence. A chart review of 842 adults with SCD, seen 3/2017–3/2021 in the Montefiore healthcare system (All Patients), was done. Only about half of All Patients (n = 842) had >1 DFE during the study period (Total Examined Patients, n = 415). The Total Examined Patients were categorized as screening, those without retinopathy (Retinopathy−, n = 199), or follow-up, including individuals previously diagnosed with retinopathy (Retinopathy+, n = 216). Only 40.3% of screening patients (n = 87) had DFE at least biennially. As expected, there was a significant decrease in the average DFE rate of the Total Examined Patients after the COVID-19 pandemic started (13.6%) compared to pre-COVID (29.8%, p < 0.001). Similarly, there was a significant decrease in the screening rate of Retinopathy− patients from 18.6% on average pre-COVID to 6.7% during COVID (p < 0.001). This data shows the sickle retinopathy screening rate is low and innovative approaches may need to be employed to remedy this issue.
- 16 February 2023
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 20 (4) , 3451
Open AccessRoutine Ophthalmological Examination Rates in Adults with Sickle Cell Disease Are Low and Must Be Improved
The American Academy of Ophthalmology and the National Heart, Lung and Blood Institute recommend patients with sickle cell disease (SCD) undergo dilated funduscopic exams (DFE) every 1–2 years to screen for sickle retinopathy. There is a paucity of data on the adherence rate to these guidelines; a retrospective study was performed to evaluate our institution’s adherence. A chart review of 842 adults with SCD, seen 3/2017–3/2021 in the Montefiore healthcare system (All Patients), was done. Only about half of All Patients (n = 842) had >1 DFE during the study period (Total Examined Patients, n = 415). The Total Examined Patients were categorized as screening, those without retinopathy (Retinopathy−, n = 199), or follow-up, including individuals previously diagnosed with retinopathy (Retinopathy+, n = 216). Only 40.3% of screening patients (n = 87) had DFE at least biennially. As expected, there was a significant decrease in the average DFE rate of the Total Examined Patients after the COVID-19 pandemic started (13.6%) compared to pre-COVID (29.8%, p < 0.001). Similarly, there was a significant decrease in the screening rate of Retinopathy− patients from 18.6% on average pre-COVID to 6.7% during COVID (p < 0.001). This data shows the sickle retinopathy screening rate is low and innovative approaches may need to be employed to remedy this issue.